Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Liabilities and Shareholders Equity (2021 - 2025)

Historic Liabilities and Shareholders Equity for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $372.8 million.

  • ARS Pharmaceuticals' Liabilities and Shareholders Equity rose 7132.41% to $372.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 5158.15%. This contributed to the annual value of $351.2 million for FY2024, which is 5058.79% up from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Liabilities and Shareholders Equity stood at $372.8 million, which was up 7132.41% from $313.5 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Liabilities and Shareholders Equity registered a high of $382.2 million during Q1 2021, and its lowest value of $61.4 million during Q4 2021.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $281.4 million (2022), whereas its average is $282.4 million.
  • The largest annual percentage gain for ARS Pharmaceuticals' Liabilities and Shareholders Equity in the last 5 years was 35802.01% (2022), contrasted with its biggest fall of 2311.57% (2022).
  • Over the past 5 years, ARS Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $61.4 million in 2021, then skyrocketed by 358.02% to $281.4 million in 2022, then fell by 17.14% to $233.2 million in 2023, then surged by 50.59% to $351.2 million in 2024, then increased by 6.17% to $372.8 million in 2025.
  • Its Liabilities and Shareholders Equity was $372.8 million in Q3 2025, compared to $313.5 million in Q2 2025 and $327.3 million in Q1 2025.